182 related articles for article (PubMed ID: 24777122)
1. RUNX family members are covalently modified and regulated by PIAS1-mediated sumoylation.
Kim JH; Jang JW; Lee YS; Lee JW; Chi XZ; Li YH; Kim MK; Kim DM; Choi BS; Kim J; Kim HM; van Wijnen A; Park I; Bae SC
Oncogenesis; 2014 Apr; 3(4):e101. PubMed ID: 24777122
[TBL] [Abstract][Full Text] [Related]
2. SUMO3 modification by PIAS1 modulates androgen receptor cellular distribution and stability.
Yang N; Liu S; Qin T; Liu X; Watanabe N; Mayo KH; Li J; Li X
Cell Commun Signal; 2019 Nov; 17(1):153. PubMed ID: 31752909
[TBL] [Abstract][Full Text] [Related]
3. The transcriptional activity of co-activator AIB1 is regulated by the SUMO E3 ligase PIAS1.
Li S; Yang C; Hong Y; Bi H; Zhao F; Liu Y; Ao X; Pang P; Xing X; Chang AK; Xiao L; Zhang Y; Wu H
Biol Cell; 2012 May; 104(5):287-96. PubMed ID: 22283414
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylation of protein inhibitor of activated STAT1 (PIAS1) by MAPK-activated protein kinase-2 inhibits endothelial inflammation via increasing both PIAS1 transrepression and SUMO E3 ligase activity.
Heo KS; Chang E; Takei Y; Le NT; Woo CH; Sullivan MA; Morrell C; Fujiwara K; Abe J
Arterioscler Thromb Vasc Biol; 2013 Feb; 33(2):321-9. PubMed ID: 23202365
[TBL] [Abstract][Full Text] [Related]
5. The transcriptional repression activity of KyoT2 on the Notch/RBP-J pathway is regulated by PIAS1-catalyzed SUMOylation.
Wang J; Qin H; Liang J; Zhu Y; Liang L; Zheng M; Han H
J Mol Biol; 2007 Jun; 370(1):27-38. PubMed ID: 17509614
[TBL] [Abstract][Full Text] [Related]
6. PIAS1 impedes vascular endothelial injury and atherosclerotic plaque formation in diabetes by blocking the RUNX3/TSP-1 axis.
Jin Q; Zhao T; Lin L; Yao X; Teng Y; Zhang D; Jin Y; Yang M
Hum Cell; 2023 Nov; 36(6):1915-1927. PubMed ID: 37584829
[TBL] [Abstract][Full Text] [Related]
7. Necdin promotes ubiquitin-dependent degradation of PIAS1 SUMO E3 ligase.
Gur I; Fujiwara K; Hasegawa K; Yoshikawa K
PLoS One; 2014; 9(6):e99503. PubMed ID: 24911587
[TBL] [Abstract][Full Text] [Related]
8. Protein inhibitor of activated STAT 1 (PIAS1) is identified as the SUMO E3 ligase of CCAAT/enhancer-binding protein β (C/EBPβ) during adipogenesis.
Liu Y; Zhang YD; Guo L; Huang HY; Zhu H; Huang JX; Liu Y; Zhou SR; Dang YJ; Li X; Tang QQ
Mol Cell Biol; 2013 Nov; 33(22):4606-17. PubMed ID: 24061474
[TBL] [Abstract][Full Text] [Related]
9. PIAS1-mediated sumoylation of focal adhesion kinase activates its autophosphorylation.
Kadaré G; Toutant M; Formstecher E; Corvol JC; Carnaud M; Boutterin MC; Girault JA
J Biol Chem; 2003 Nov; 278(48):47434-40. PubMed ID: 14500712
[TBL] [Abstract][Full Text] [Related]
10. RAC-LATS1/2 signaling regulates YAP activity by switching between the YAP-binding partners TEAD4 and RUNX3.
Jang JW; Kim MK; Lee YS; Lee JW; Kim DM; Song SH; Lee JY; Choi BY; Min B; Chi XZ; Bae SC
Oncogene; 2017 Feb; 36(7):999-1011. PubMed ID: 27425596
[TBL] [Abstract][Full Text] [Related]
11. Modification of cardiac transcription factor Gata6 by SUMO.
Chen H; Sun W; Zhu J; Yuan H; Chu M; Wen B
Biochimie; 2020 Mar; 170():212-218. PubMed ID: 32017966
[TBL] [Abstract][Full Text] [Related]
12. Tumor Suppressor p14ARF Enhances IFN-γ-Activated Immune Response by Inhibiting PIAS1 via SUMOylation.
Alagu J; Itahana Y; Sim F; Chao SH; Bi X; Itahana K
J Immunol; 2018 Jul; 201(2):451-464. PubMed ID: 29848755
[TBL] [Abstract][Full Text] [Related]
13. The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA.
Rabellino A; Carter B; Konstantinidou G; Wu SY; Rimessi A; Byers LA; Heymach JV; Girard L; Chiang CM; Teruya-Feldstein J; Scaglioni PP
Cancer Res; 2012 May; 72(9):2275-84. PubMed ID: 22406621
[TBL] [Abstract][Full Text] [Related]
14. Akt SUMOylation regulates cell proliferation and tumorigenesis.
Li R; Wei J; Jiang C; Liu D; Deng L; Zhang K; Wang P
Cancer Res; 2013 Sep; 73(18):5742-53. PubMed ID: 23884910
[TBL] [Abstract][Full Text] [Related]
15. PIAS1 interacts with and represses SOX9 transactivation activity.
Oh HJ; Kido T; Lau YF
Mol Reprod Dev; 2007 Nov; 74(11):1446-55. PubMed ID: 17440973
[TBL] [Abstract][Full Text] [Related]
16. Protein inhibitor of activated signal transducer and activator of transcription 1 interacts with the N-terminal domain of mineralocorticoid receptor and represses its transcriptional activity: implication of small ubiquitin-related modifier 1 modification.
Tallec LP; Kirsh O; Lecomte MC; Viengchareun S; Zennaro MC; Dejean A; Lombès M
Mol Endocrinol; 2003 Dec; 17(12):2529-42. PubMed ID: 14500761
[TBL] [Abstract][Full Text] [Related]
17. Sumoylated SnoN represses transcription in a promoter-specific manner.
Hsu YH; Sarker KP; Pot I; Chan A; Netherton SJ; Bonni S
J Biol Chem; 2006 Nov; 281(44):33008-18. PubMed ID: 16966324
[TBL] [Abstract][Full Text] [Related]
18. Distinct association of RUNX family expression with genetic alterations and clinical outcome in acute myeloid leukemia.
Zhao Y; Zhang T; Zhao Y; Zhou J
Cancer Biomark; 2020; 29(3):387-397. PubMed ID: 32741803
[TBL] [Abstract][Full Text] [Related]
19. PIAS1 protects against myocardial ischemia-reperfusion injury by stimulating PPARγ SUMOylation.
Xie B; Liu X; Yang J; Cheng J; Gu J; Xue S
BMC Cell Biol; 2018 Nov; 19(1):24. PubMed ID: 30419807
[TBL] [Abstract][Full Text] [Related]
20. Extracellular signal-regulated kinase 5 SUMOylation antagonizes shear stress-induced antiinflammatory response and endothelial nitric oxide synthase expression in endothelial cells.
Woo CH; Shishido T; McClain C; Lim JH; Li JD; Yang J; Yan C; Abe J
Circ Res; 2008 Mar; 102(5):538-45. PubMed ID: 18218985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
